Press release - June 30th, 2014
Cerbomed GmbH at the 11th European Congress on Epileptology in Stockholm
ERLANGEN/STOCKHOLM, 30.06.2014 – From June 30th until July 3rd 2014 the medical device company cerbomed GmbH from Erlangen, Germany, will present a further therapy option for people suffering from epilepsies at the 11th European Congress on Epileptology in Stockholm:
The transcutaneous Vagus Nerve Stimulation (t-VNS) with the therapy device NEMOS.
About t-VNS with NEMOS
Transcutaneous Vagus Nerve Stimulation with NEMOS offers a further therapy option to epilepsy patients, who suffer from continued occurrence of seizures, despite appropriate treatment with anticonvulsive drugs.
The t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
The treatment with NEMOS is carried out autonomously by the patients by using the therapy device NEMOS, a special stimulator and a dedicated ear electrode, that sends out the electrical impulses. With NEMOS a targeted stimulation of the vagus nerve gets possible without the need of a surgery.
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
The transcutaneous Vagus Nerve Stimulation received the European clearance (CE mark) for the treatment of epilepsies, depression and pain. Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.
The therapy device NEMOS is available for treating epilepsies in Germany, Austria, Switzerland and Italy.